BioCentury | Jun 12, 2014
Targets & Mechanisms

Putting SMYD3 on the MAP

...NASDAQ:AMBI) CEP-32496 Melanoma BRAF Phase I/II Eli Lilly and Co. (NYSE:LLY); Deciphera Pharmaceuticals LLC LY3009120 (DP-4978...
BioCentury | Apr 14, 2014
Clinical News

LY3009120: Phase I started

...Late last year, Deciphera began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral DP-4978...
...Pharmaceuticals LLC , Lawrence, Kan. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY3009120 , DP-4978...
BioCentury | Apr 25, 2013
Targets & Mechanisms

MERTK: upstream from BRAF

...Biosciences Corp. and Teva Pharmaceutical Industries Ltd. , is in preclinical testing to treat melanoma. DP-4978...
BioCentury | Oct 15, 2012
Company News

Deciphera cancer news

...a backup compound to DCC-2701. Additionally, Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) is developing DP-4978...
...pharma under the deal. According to Deciphera, the payment was triggered by the selection of DP-4978...
Items per page:
1 - 4 of 4